Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

De Europese erfrechtverklaring

Since 17 August 2015, the Succession Regulation is applicable in the European Member States, establishing uniform rules on the jurisdiction and applicable law for cross-border successions. The Succession Regulation also introduces a European Certificate of Succession, allowing heirs, legatees, administrators of the estate and executors of wills to prove their legal capacity and rights in another Member State. As such, the European Certificate of Succession offers a supranational alternative to national instruments with a similar purpose which exist in many Member States, but often do not produce their full effects abroad. In general, the European Certificate of Succession's legal regime is comprehensive and practical, especially as regards its content and procedural aspects. Nevertheless, there remain a few fundamental conceptual lacunae. In particular, it is unclear to what extent the European Certificate of Succession can give rise to registration in the Member States' land registers, as well as how the European Certificate and the corresponding national instruments relate to each other. The aim of the research project is to develop a conceptual framework for these lacunae.status: publishe

A Model for the Use of the European Certificate of Succession for Property Registration

status: publishe

A model for the use of the European certificate of succession for property registration

status: publishe

Koorddansen in het familiaal vermogensrecht – Naar een nieuw evenwicht tussen de belangen van de kinderen en die van de langstlevende echtgenoot

status: publishe

De Europese Erfrechtverordening: krachtlijnen en knelpunten

status: publishe

De materieelrechtelijke implicaties van de Europese Erfrechtverordening

status: publishe

Kompas voor een nieuw samenwoningsrecht: neutraal, coherent en compensatie- en behoeftegericht

status: publishe